CJC-1295
A GHRH analog commonly discussed in growth-hormone optimization circles and research-market peptide stacks.
Also referenced as: Drug Affinity Complex CJC-1295
Also appears in: Performance
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when CJC-1295 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.
Drug Affinity Complex CJC-1295
No FDA label signal · 1 trials · 33 PubMed results
CJC-1295 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
CJC-1295 has 1 name-matched clinical trial (highest phase: Phase 2) and 33 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What CJC-1295 is
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It is often discussed in research-market contexts as a way to stimulate endogenous growth-hormone signaling rather than supplying growth hormone directly.
Why it matters
It sits near the center of the “GH secretagogue” conversation, especially when paired in discussion with compounds like ipamorelin. That makes it a useful profile for understanding the difference between growth-hormone pathway signaling and actual FDA-approved hormone medicines.
Regulatory context
CJC-1295 is not FDA-approved as a peptide medicine in the United States. Most discussion around it belongs to the research-market or performance-oriented side of the peptide world.
Practical reading note
This is one of the clearest examples of a peptide that gets discussed as if it were a routine wellness therapy even though its real regulatory footing is much looser.